Beutel Goodman & Co Ltd. Lowers Stake in Amgen, Inc. (AMGN)

Share on StockTwits

Beutel Goodman & Co Ltd. cut its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 609,183 shares of the medical research company’s stock after selling 8,347 shares during the period. Beutel Goodman & Co Ltd. owned about 0.09% of Amgen worth $97,688,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Principal Financial Group Inc. increased its stake in shares of Amgen by 1.4% in the first quarter. Principal Financial Group Inc. now owns 1,187,759 shares of the medical research company’s stock valued at $202,489,000 after buying an additional 15,948 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in Amgen by 2.0% in the second quarter. Fisher Asset Management LLC now owns 149,006 shares of the medical research company’s stock valued at $27,505,000 after acquiring an additional 2,942 shares during the last quarter. Hudson Valley Investment Advisors Inc. ADV boosted its holdings in Amgen by 3.8% in the second quarter. Hudson Valley Investment Advisors Inc. ADV now owns 12,166 shares of the medical research company’s stock valued at $2,246,000 after acquiring an additional 445 shares during the last quarter. Capital Investment Advisors LLC boosted its holdings in Amgen by 8.7% in the second quarter. Capital Investment Advisors LLC now owns 24,102 shares of the medical research company’s stock valued at $4,449,000 after acquiring an additional 1,919 shares during the last quarter. Finally, Osborn Williams & Donohoe LLC boosted its holdings in Amgen by 1.3% in the second quarter. Osborn Williams & Donohoe LLC now owns 24,756 shares of the medical research company’s stock valued at $4,570,000 after acquiring an additional 322 shares during the last quarter. Institutional investors own 82.37% of the company’s stock.

Several equities analysts recently issued reports on the company. Cann restated a “buy” rating and set a $224.00 target price on shares of Amgen in a report on Monday, October 1st. Jefferies Financial Group restated a “buy” rating and set a $220.00 target price on shares of Amgen in a report on Monday, October 1st. Oppenheimer restated a “buy” rating and set a $224.00 target price on shares of Amgen in a report on Tuesday, October 2nd. Royal Bank of Canada set a $193.00 target price on Amgen and gave the stock a “neutral” rating in a report on Friday, September 28th. Finally, Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $234.00 target price on the stock in a report on Monday, October 1st. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $204.55.

Shares of Amgen stock opened at $190.75 on Wednesday. Amgen, Inc. has a 52-week low of $163.31 and a 52-week high of $210.19. The company has a market capitalization of $119.20 billion, a P/E ratio of 13.48, a PEG ratio of 1.95 and a beta of 1.37. The company has a current ratio of 3.08, a quick ratio of 2.84 and a debt-to-equity ratio of 2.05.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.45 by $0.24. Amgen had a return on equity of 54.14% and a net margin of 9.44%. The business had revenue of $5.90 billion for the quarter, compared to analyst estimates of $5.78 billion. During the same quarter last year, the firm earned $3.27 EPS. Amgen’s revenue for the quarter was up 2.3% compared to the same quarter last year. Research analysts forecast that Amgen, Inc. will post 14.24 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 7th. Shareholders of record on Friday, November 16th will be given a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 2.77%. The ex-dividend date of this dividend is Thursday, November 15th. Amgen’s dividend payout ratio (DPR) is 41.97%.

TRADEMARK VIOLATION NOTICE: This article was published by Week Herald and is the property of of Week Herald. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://weekherald.com/2018/11/07/beutel-goodman-co-ltd-lowers-stake-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Featured Story: Stop Order

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply